JPMorgan Chase & Co’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $636K | Sell |
47,654
-2,552,803
| -98% | -$34.1M | ﹤0.01% | 3953 |
|
|
2025
Q1 | $26.5M | Buy |
2,600,457
+2,387,026
| +1,118% | +$24.3M | ﹤0.01% | 1516 |
|
|
2024
Q4 | $3.38M | Buy |
213,431
+182,314
| +586% | +$2.89M | ﹤0.01% | 3056 |
|
|
2024
Q3 | $1.81M | Buy |
31,117
+422
| +1% | +$24.5K | ﹤0.01% | 3323 |
|
|
2024
Q2 | $1.4M | Sell |
30,695
-24,715
| -45% | -$1.13M | ﹤0.01% | 3309 |
|
|
2024
Q1 | $3.67M | Sell |
55,410
-7,234
| -12% | -$479K | ﹤0.01% | 2759 |
|
|
2023
Q4 | $2.49M | Buy |
62,644
+9,575
| +18% | +$381K | ﹤0.01% | 3006 |
|
|
2023
Q3 | $1.69M | Buy |
53,069
+23,379
| +79% | +$745K | ﹤0.01% | 3095 |
|
|
2023
Q2 | $1.19M | Buy |
29,690
+6,270
| +27% | +$252K | ﹤0.01% | 3319 |
|
|
2023
Q1 | $1M | Sell |
23,420
-18,061
| -44% | -$771K | ﹤0.01% | 3451 |
|
|
2022
Q4 | $1.99M | Buy |
41,481
+23,710
| +133% | +$1.14M | ﹤0.01% | 2961 |
|
|
2022
Q3 | $669K | Buy |
17,771
+2,547
| +17% | +$95.9K | ﹤0.01% | 3583 |
|
|
2022
Q2 | $420K | Sell |
15,224
-22,304
| -59% | -$615K | ﹤0.01% | 3974 |
|
|
2022
Q1 | $2.04M | Buy |
37,528
+4,329
| +13% | +$235K | ﹤0.01% | 3159 |
|
|
2021
Q4 | $1.94M | Buy |
33,199
+22,697
| +216% | +$1.33M | ﹤0.01% | 3255 |
|
|
2021
Q3 | $415K | Buy |
10,502
+1,231
| +13% | +$48.6K | ﹤0.01% | 4061 |
|
|
2021
Q2 | $393K | Buy |
9,271
+2,882
| +45% | +$122K | ﹤0.01% | 4128 |
|
|
2021
Q1 | $393K | Buy |
6,389
+555
| +10% | +$34.1K | ﹤0.01% | 4172 |
|
|
2020
Q4 | $411K | Buy |
5,834
+3,237
| +125% | +$228K | ﹤0.01% | 3855 |
|
|
2020
Q3 | $102K | Buy |
2,597
+254
| +11% | +$9.98K | ﹤0.01% | 4037 |
|
|
2020
Q2 | $88K | Buy |
+2,343
| New | +$88K | ﹤0.01% | 4008 |
|